BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 22 October 1997
Pacific Growth Equities acted as sole placement agent on the offering. Following this transaction, the company has 13.1 million weighted average shares outstanding.
"These new funds will allow Calypte to, first, complete the scale-up of manufacturing for our urine-based test for HIV-1," said Jack Davis, president and chief executive officer. "Second, they will allow us to initiate the development of additional urine-based diagnostic tests including the Calypte HIV-1 urine test for Home Collection, and to undertake the clinical trials required for this application."
Calypte announced on September 18th that the manufacturer of the Western Blot confirmatory test which is used in conjunction with the Calypte Biomedical HIV-1 urine screening assay had received, from the Food and Drug Administration, a "Review Complete" letter. The "Review Complete" letter indicated that the kit may be marketed once the company has addressed the labeling issues posed in the "Review Complete" letter and the product labeling review process has been completed.
Calypte Biomedical Corp. is an Alameda and Berkeley, California based health care company dedicated to the development and commercialization of urine-based diagnostic products and services for HIV-1, sexually transmitted diseases and other chronic illnesses.
Statements in this press release that are not historical facts are forward-looking statements, including the statements regarding the use of funds, the development of additional tests, the filing of applications with the FDA and approval of the confirmatory test. Actual results may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon the timely development and regulatory approval of existing and proposed products as well as the company's ability, directly or through third parties, to successfully manufacture and market its existing and future products. These factors are more fully discussed in the company's most recent quarterly report on form 10-Q.
--30--cmc/sf* ms/eh
CONTACT: Calypte Biomedical Corp. Jack Davis or John DiPietro, 510/814-8500
Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com
Copyright (c) 1997/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
971022
BW971011
Copyright © 1997 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .